Cytokinetics, Incorporated (CYTK)
| Market Cap | 7.55B |
| Revenue (ttm) | 88.04M |
| Net Income (ttm) | -784.96M |
| Shares Out | 124.24M |
| EPS (ttm) | -6.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,213,104 |
| Open | 62.86 |
| Previous Close | 61.60 |
| Day's Range | 60.66 - 63.24 |
| 52-Week Range | 29.31 - 70.98 |
| Beta | 0.48 |
| Analysts | Strong Buy |
| Price Target | 89.26 (+46.89%) |
| Earnings Date | May 5, 2026 |
About CYTK
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h... [Read more]
Financial Performance
In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for CYTK stock is "Strong Buy." The 12-month stock price target is $89.26, which is an increase of 46.89% from the latest price.
News
Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Co...
Cytokinetics to Announce First Quarter Results on May 5, 2026
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 5, 2026 at 4:00 PM...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 15, 2026 it granted stock options to purchase an aggregate of 49...
Cytokinetics Transcript: 25th Annual Needham Virtual Healthcare Conference
MYQORZO launched in the US in early 2026 with rapid uptake, strong differentiation, and Medicare access nearing parity with competitors. European launch begins in Germany, with broader rollout planned. Key clinical catalysts include ACACIA-HCM phase III data in Q2 and ongoing pipeline expansion.
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company's management team are scheduled to participate in ...
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten) SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, ...
Cytokinetics Transcript: Barclays 28th Annual Global Healthcare Conference
MYQORZO's U.S. launch shows strong early adoption and high prescriber awareness, with European and Asian launches underway. The ACACIA-HCM trial aims to expand indications, with results expected in Q2. The pipeline includes advanced heart failure and HFpEF programs, supporting a specialty cardiology focus.
Cytokinetics Transcript: The Citizens Life Sciences Conference 2026
ACACIA-HCM trial results for Myqorzo in non-obstructive HCM are expected in Q2, potentially doubling its addressable market if positive. Early launch data show strong physician engagement and rapid uptake, with a differentiated product profile and strategic plans to expand into broader heart failure populations.
Cytokinetics Transcript: Leerink Global Healthcare Conference 2026
Transitioning to a global commercial stage, MYQORZO’s launch in oHCM is off to a strong start, with label expansion into nHCM expected to drive further growth. Pipeline programs in heart failure and disciplined European rollout support long-term value creation.
Cytokinetics to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following ...
Cytokinetics Earnings Call Transcript: Q4 2025
MYQORZO received approvals in the U.S., China, and EU, launching with strong initial demand and rapid HCP engagement. Financials show increased revenues and expenses, with a net loss reflecting commercial and R&D investments. Key clinical and regulatory milestones are expected in 2026.
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for ...
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorpora...
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4...
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
Grants Awarded to Two Patient Advocacy Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq...
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Inco...
The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ:...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 15, 2026 it granted stock options to purchase an aggregate of 2...
Cytokinetics Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company has launched Mycorrhiza for OHCM in the US and China, with European approval expected soon, and is targeting rapid market penetration through a differentiated clinical profile, REMS, and patient support. Expansion into NHCM could double the addressable market, with key data readouts and label expansion anticipated in 2024.
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I.
Cytokinetics Wins FDA Nod For Heart Drug Myqorzo
On Friday, the U.S. Food and Drug Administration (FDA) approved Cytokinetics Incorporated's (NASDAQ: CYTK) Myqorzo (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve...
Cytokinetics Transcript: FDA Announcement
FDA approved Myqorzo for symptomatic obstructive HCM in adults, based on strong phase III data showing significant improvements in exercise capacity and symptoms. The label features flexible dosing, minimal drug interactions, and a tailored REMS, with U.S. launch set for January and global expansion planned.
US FDA approves Cytokinetics' heart disease drug
The U.S. Food and Drug Administration has approved Cytokinetics' drug to treat a rare heart condition, the company said on Friday.
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO, Calif....